1,2 If youve had diabetic ketoacidosis in the past, weight-loss injections also arent prescribed
After some mild bloating and a lot of time spent in the restroom the appetite control really started to kick in
Similarly, tirzepatide, a dual GLP-1/GIP receptor agonist, achieved an average weight loss of 15% at 72 weeks in non-diabetic obese patients, with greater reductions observed at the higher 15 mg dose.77 The most frequently reported adverse effects of GLP-1RAs include nausea, vomiting, and diarrhea, which are dose-dependent and more prevalent with short-acting formulations than with long-acting agents
These combined effects result in improved postprandial and fasting glucose levels, along with substantial weight loss that varies by indication and dosetypically 5-13% in type 2 diabetes trials and up to 15-20% in obesity trials at the highest doses (15 mg)
doi: 10.1161/CIRCULATIONAHA.122.059595